We have heard from a number of women who claim to have experienced similar complications following uterine morcellation. The specifics of this case also echoe the allegations put forth in a number of other morcellator lawsuits filed in recent months.
New York, New York (PRWEB) August 27, 2014
Power morcellator lawsuits (http://www.morcellatorlawsuit2015.com) continue to be filed in U.S. courts on behalf of women who allegedly experienced the spread of dangerous cancers due to uterine morcellation, Bernstein Liebhard LLP reports. According to court documents, one of the most recent cases was filed on August 18th in the U.S. District Court, Northern District of New York, on behalf of a hysterectomy patient who claims the use of a power morcellator manufactured Karl Storz Endoscopy - America caused the upstaging of leiomyosarcoma, a particularly aggressive form of uterine cancer.(Case No. 3:14-cv-01024-TJM-DEP)
According to the complaint, the Plaintiff had no signs of cancer prior to undergoing a laparoscopic supracervical hysterectomy for uterine fibroids in August 2011. During the procedure, the woman’s surgeon used a Rotocut G1 morcellator to cut uterine tissue into small pieces in order to facilitate its removal via abdominal incision. Within months of the procedure, the Plaintiff was diagnosed with leiomyosarcoma.
“We have heard from a number of women who claim to have experienced similar complications following uterine morcellation. The specifics of this case also echoe the allegations put forth in a number of other morcellator lawsuits filed in recent months,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is now offering hysterectomy cancer lawsuit reviews to women who suffered uterine sarcoma or other cancers allegedly spread by morcellation.
Power Morcellators and Cancer
On April 17, 2014, a U.S. Food & Drug Administration (FDA) alert discouraged doctors from using the devices in laparoscopic hysterectomy and fibroid removals, because of the risk that they could promote the spread of undetected uterine sarcomas and other cancers. Roughly 1 in 350 women who undergo fibroid removal may also suffer from undiagnosed uterine sarcoma, while 1 in 498 has undetected leiomyosarcoma. Such malignancies are difficult to detect prior to surgery, and their dissemination during uterine morcellation can quickly upstage the cancer and significant reduce a woman’s chances for long-term survival, the FDA said.
In July, the FDA convened a meeting of outside advisors to discuss the procedure’s risks and benefits. During the proceeding, the panel members heard emotional testimony from a number of cancer patients and their loved ones, many of whom urged the FDA to ban power morcellators.* Shortly after the FDA’s July meeting, a power morcellator recall was announced by Johnson & Johnson’s for three devices manufactured by Ethicon, Inc. unit. ** Highmark, Inc., one of the nation’s largest Blue Cross and Blue Shield insurers, announced last month that it would no longer cover uterine morcellation.***
Women who allegedly experienced the spread of cancer due to uterine morcellation may be eligible to file their own power morcellator lawsuit. To learn more, please visit Bernstein Liebhard LLP’s website, or call the Firm directly for a free, no-obligation case review at 800-511-5092.
*bostonglobe.com/lifestyle/health-wellness/2014/07/11/agreement-reached-whether-fda-should-ban-hysterectomy-cutting-tool/EkXZaFAUUnT5HZ7DBQvWbM/story.html, Boston Globe, July 11, 2014
**ethicon.com/sites/default/files/managed-documents/Ethicon%20Morcellation%20Devices%20Customer%20Letter%20Final.pdf, Ethicon, Inc., July 30, 2014
***in.reuters.com/article/2014/08/02/highmark-procedure-idINL2N0Q80IY20140802, Reuters, August 3, 2014
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP